Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Arformoterol
Drug ID BADD_D00159
Description Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. Arformoterol inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long acting beta agonists for the treatment of asthma.
Indications and Usage A bronchodilator used for the long term, symptomatic treatment of reversible bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Marketing Status approved; investigational
ATC Code R03CC15; R03AC13
DrugBank ID DB01274
KEGG ID D07463
MeSH ID D000068759
PubChem ID 3083544
TTD Drug ID D0D1DI
NDC Product Code Not Available
UNII F91H02EBWT
Synonyms Formoterol Fumarate | Formoterol Fumarate, ((R*,R*)-(+-))-isomer | 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate | BD 40A | Formoterol | Eformoterol | Oxis | Arformoterol | Formoterol, ((R*,R*)-(+-))-isomer | Foradil
Chemical Information
Molecular Formula C19H24N2O4
CAS Registry Number 67346-49-0
SMILES CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metabolic acidosis14.01.01.003--Not Available
Muscle spasms15.05.03.004--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral02.05.04.007; 14.05.06.011; 08.01.07.007--
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Paralysis17.01.04.004--Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Pyuria20.08.02.016; 11.01.08.043--Not Available
Rash23.03.13.001--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Retroperitoneal haemorrhage12.01.17.018; 24.07.01.017; 07.07.02.002--
Rheumatoid arthritis15.01.03.001; 10.04.06.001--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin hypertrophy23.01.04.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Supraventricular tachycardia02.03.03.012--
Tachycardia02.03.02.007--Not Available
Tendinous contracture15.07.01.001--Not Available
Tension19.06.02.005--Not Available
Tooth abscess07.09.01.003; 11.01.04.003--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages